sorry but IMHO this looks like an overblown announcement
-they’re trumpeting a “breakthrough” on the basis of what? An unspecified target that hasn’t even gone into preclinical testing yet.
there’s big attrition from ID to preclinical to clinical phase1 so higher chance it’ll fail
••might be better to treat with some healthy scepticism until this hits phase 1 at earliest or market sees some evidence of this “breakthrough” in a peer review publication.
just my opinion
DYOR
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline, page-8
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $11.03K | 105.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 418372 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 102513 | 3 |
View Market Depth
| Last trade - 15.45pm 27/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |